Shielding
What Matters
AEGIS BIO develops small molecules designed to improve
the efficacy and tolerability of cancer treatments.
the efficacy and tolerability of cancer treatments.
Preclinical-stage biotech
Two-candidate pipeline
In vivo proof of concept
i-Lab 2026 laureate
Toxicity remains a major limitation of cancer treatment
Severe side effects can compromise efficacy, restrict clinical use and prevent regulatory approval.
The Cisplatin Case
AEGIS BIO develops small molecules for use with DNA-damaging cancer treatments like cisplatin
A combination designed to reduce toxicity, enhance efficacy and improve patient outcomes.
Severe toxicity
Reduced toxicity
Dose reduction
Preserved treatment intensity
Compromised treatment
Enhanced antitumor activity
Preclinical evidence
Ototoxicity
In vivo protection demonstrated
Nephrotoxicity
Protective activity observed in vivo
Peripheral neurotoxicity
In vivo validation underway
Initially focused on cisplatin, AEGIS BIO’s approach has the potential to extend to a broader range of DNA-damaging cancer treatments.
Advancing a differentiated supportive oncology pipeline
TIX047 • Lead candidate
Designed to reduce multiple toxicities associated with cisplatin while enhancing its antitumor activity.
Indications: Pediatric cancers · Head and neck cancers · Testicular cancers
- Lead identification
- Candidate selection
- Preclinical efficacy
- PK/PD & formulation
- IND-enabling
- Clinical development
TIX022 • Preclinical candidate
A second validated candidate supporting the breadth and continuity of AEGIS BIO’s small-molecule pipeline.
Indications: Undisclosed
- Lead identification
- Candidate selection
- Preclinical efficacy
- PK/PD & formulation
- IND-enabling
- Clinical development
Scientific, clinical and business expertise
Chames Kermi
Co-founder & CEO
Chames KERMI, PharmD, PhD, MBA
Co-Founder & CEO
Chames Kermi is a pharmacist, PhD-trained scientist in human genetics and cell biology, and MBA graduate from Babson College, with more than 12 years of experience spanning translational research, drug development, biopharmaceutical innovation, entrepreneurship, and venture investing. His career includes positions at Sanofi, Stanford University School of Medicine, and Pfizer, where he served as Principal Scientist and Project Manager at the Centers for Therapeutic Innovation, leading cross-functional therapeutic programs in oncology and immunotherapy and managing collaborations with biotechnology companies, academic institutions, and CROs.
Alongside his scientific career, Chames has developed significant experience in life sciences investing and company creation. He served as a Life Science Partner at Advantary Capital Partners, where he sources and evaluates early-stage biotech and healthtech companies, and an Investment Consultant at Witucki Capital, supporting financing activities and company-investor relationships. He has also contributed to venture evaluation and investor-facing diligence associated with Alumni Ventures’ Cardinal/Spike Ventures ecosystem.
His background combines deep expertise in preclinical and translational drug development with experience in biotech strategy, intellectual property, regulatory development, fundraising, market assessment, and venture due diligence.
As Founder and CEO of AEGIS BIO, Chames leads the company’s scientific and corporate strategy, therapeutic development programs, strategic partnerships, financing, and investor relations. AEGIS BIO is developing innovative therapies designed to reduce cisplatin-related toxicities while preserving anticancer efficacy.
Alongside his scientific career, Chames has developed significant experience in life sciences investing and company creation. He served as a Life Science Partner at Advantary Capital Partners, where he sources and evaluates early-stage biotech and healthtech companies, and an Investment Consultant at Witucki Capital, supporting financing activities and company-investor relationships. He has also contributed to venture evaluation and investor-facing diligence associated with Alumni Ventures’ Cardinal/Spike Ventures ecosystem.
His background combines deep expertise in preclinical and translational drug development with experience in biotech strategy, intellectual property, regulatory development, fundraising, market assessment, and venture due diligence.
As Founder and CEO of AEGIS BIO, Chames leads the company’s scientific and corporate strategy, therapeutic development programs, strategic partnerships, financing, and investor relations. AEGIS BIO is developing innovative therapies designed to reduce cisplatin-related toxicities while preserving anticancer efficacy.
Jing Wang
Co-founder & Scientific Lead
Dr. Jing Wang, MD, PhD
Co-founder & Scientific led | ENT Physician | INSERM Research Director | Translational Neuroscience & Hearing Therapeutics
Dr. Jing Wang is an ENT physician and INSERM Research Director at the Montpellier Neuroscience Institute (INM), where she leads research on hearing disorders and innovative therapies. With an international academic, clinical and industrial R&D background, she specializes in translational research on cochlear damage, hearing loss and chemotherapy-induced ototoxicity, spanning disease mechanisms, target discovery, preclinical validation and clinical translation, including pharmacological and gene-therapy approaches.
Author of 60+ scientific publications and contributor to international patent families, Dr. Wang has a strong track record in therapeutic development, clinical programs, technology transfer and industrial partnerships. She was involved in the preclinical and clinical development of AM-111, including a Phase III program.
As Co-founder and Scientific Advisor of AEGIS BIO, Jing contributes to the company’s scientific and translational strategy, with a particular focus on the biological mechanisms of chemotherapy-induced toxicity, biomarker strategy, and the validation of preclinical models and endpoints.
Author of 60+ scientific publications and contributor to international patent families, Dr. Wang has a strong track record in therapeutic development, clinical programs, technology transfer and industrial partnerships. She was involved in the preclinical and clinical development of AM-111, including a Phase III program.
As Co-founder and Scientific Advisor of AEGIS BIO, Jing contributes to the company’s scientific and translational strategy, with a particular focus on the biological mechanisms of chemotherapy-induced toxicity, biomarker strategy, and the validation of preclinical models and endpoints.
Frederic Venail
Co-founder & Clinical Lead
Frédéric Venail, MD, PhD, MBA
Co-founder and Clinical & Scientific Advisor | ENT surgeon | neuroscientist
Frédéric Venail is an ENT surgeon and neuroscientist specializing in otology and hearing disorders. He spent ten years as Professor of Otolaryngology at the University of Montpellier and Montpellier University Hospital, combining clinical practice with translational research on cochlear biology, hearing preservation, fibrosis and auditory implants.
He has authored more than 80 peer-reviewed publications and co-invented two patents, and has led numerous clinical and translational research programs in collaboration with academic and industry partners.
As Co-founder and Clinical & Scientific Advisor of AEGIS BIO, Frédéric contributes to the company’s scientific, medical and clinical strategy, with a particular focus on translating advances in inner-ear biology into new approaches to prevent ototoxicity and preserve hearing.
He has authored more than 80 peer-reviewed publications and co-invented two patents, and has led numerous clinical and translational research programs in collaboration with academic and industry partners.
As Co-founder and Clinical & Scientific Advisor of AEGIS BIO, Frédéric contributes to the company’s scientific, medical and clinical strategy, with a particular focus on translating advances in inner-ear biology into new approaches to prevent ototoxicity and preserve hearing.
Veronica Mohamed-Hizam
Research Engineer
Veronica Mohamed-Hizam, PhD
research engineer
Veronica Mohamed-Hizam is a Research Engineer at AEGIS BIO, with expertise in auditory neuroscience, preclinical animal models, molecular biology, histology, and functional hearing assessments including ABR and DPOAE. She supports AEGIS BIO’s preclinical R&D programs through experimental execution, data generation and analysis, and rigorous scientific documentation, contributing to the development of novel therapies aimed at preventing treatment-related toxicities.
Supported by a leading innovation ecosystem
Latest news
AEGIS BIO named a laureate of the i-Lab 2026 Innovation Competition
AEGIS BIO is proud to announce that it has been selected as a laureate of the 2026 i-Lab Innovation Competition, a flagship national program supporting high-potential deep-tech companies, operated by Bpifrance on behalf of the French State. This highly competitive…
→ Read the news
CREALIA backs AEGIS BIO’s next stage of development
AEGIS BIO is delighted to receive the support of CREALIA, providing new momentum to the company as we advance our preclinical development and prepare for the next stages of growth. This support is also a strong recognition of AEGIS BIO’s…
→ Read the news
AEGIS BIO joins Eurobiomed to strengthen its positon with Southern France’s biotech ecosystem
AEGIS BIO is proud to join Eurobiomed, one of France’s leading health innovation clusters, bringing together biotechnology companies, academic research centers, healthcare institutions, investors, and industry partners. This membership represents an important step in AEGIS BIO’s growth and strengthens our…
→ Read the news